Navigating Treatment Options for Pleural Mesothelioma: A Guide for Patients and Caregivers

ByHolly Zink
Navigating Treatment Options for Pleural Mesothelioma: A Guide for Patients and Caregivers

Pleural mesothelioma is a rare, aggressive cancer often caused by asbestos exposure. Sadly, its slow onset and few treatment choices reduce survival rates. Yet, recent pharmacological research developments provide hope for better treatments.

Understanding the Disease

Pleural mesothelioma is aggressive and resists standard treatments. Efforts to identify treatment targets have shown limited success. Patients typically live less than 16 months after diagnosis, underlining the need for better therapies.

Treatment usually involves chemotherapy, immunotherapy, and targeted therapy. Chemotherapy combines drugs like cisplatin and pemetrexed to slow tumor growth and ease symptoms.

Immunotherapy, with drugs like pembrolizumab, boosts the immune system’s fight against cancer in some patients. Meanwhile, research is ongoing on targeted therapies that block blood vessel formation and growth factor receptors to halt tumor growth.

Navigating the Treatment Journey

New drug methods could enhance pleural mesothelioma treatment. Nanoparticles and liposomes are key. They aim to boost therapy effectiveness and safety. By targeting drugs, they increase tumor levels and reduce side effects. This offers new personalized treatment options.

Facing pleural mesothelioma is tough for patients and caregivers. It’s crucial to team up with healthcare experts. This includes oncologists, surgeons, and palliative care specialists. Together, they can create a treatment plan just for patients and caregivers. Good communication, shared decisions, and support services are vital.

Research is making progress in pleural mesothelioma treatment. It’s looking into new drug treatments. This research gives hope. By working with doctors and having a strong support system, managing the disease becomes easier. It can turn into a journey of strength and empowerment.

Source:

Mirra, Luca, Giovanni L. Beretta, Daniela Lisini, Angela Marcianti, Eleonora Spampinato, Cristina Corno, Matteo Costantino, Angelo Corsico, Giulia Maria Stella, and Paola Perego. “Therapeutic Strategies to Improve the Treatment of Pleural Mesothelioma.” Current Medicinal Chemistry 31 (2024): 1–15.

 

Similar Posts

Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma
| |

Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

ByAlex Strauss

A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

Does Radiotherapy Reduce Mesothelioma Pain?
| |

Does Radiotherapy Reduce Mesothelioma Pain?

ByAlex Strauss

A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

Ape Virus Shrinks Mesothelioma Tumors in Lab
|

Ape Virus Shrinks Mesothelioma Tumors in Lab

ByAlex Strauss

A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…

Radiotherapy for Mesothelioma: Better But Still Limited
| |

Radiotherapy for Mesothelioma: Better But Still Limited

ByAlex Strauss

A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

A Second-Line Option for Mesothelioma?
| |

A Second-Line Option for Mesothelioma?

ByAlex Strauss

Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

Repeat HIPEC Improves Mesothelioma Survival
| |

Repeat HIPEC Improves Mesothelioma Survival

ByAlex Strauss

If one cytoreductive surgery and HIPEC procedure for mesothelioma is good, subsequent treatments may be even better. That is the central message of research conducted at the Moffitt Cancer Center in Florida. The study’s aim was to assess overall survival among peritoneal mesothelioma patients who had not just one, but two or more rounds of heated intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery. The cytoreduction/HIPEC approach has become popular for peritoneal mesothelioma, a treatment-resistant cancer of abdominal membranes caused by asbestos. Cytoreductive surgery involves removing as much of the mesothelioma tumor as possible from the abdomen. Because the shape and spreading pattern of mesothelioma tumors make complete cytoreduction difficult, the surgery is often followed by a rinse with a heated solution…